TIDMAPOL

RNS Number : 3810L

Apollon Formularies plc

30 December 2022

30 December 2022

Apollon Formularies Plc

Result of AGM

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international medical cannabis pharmaceutical company specialising in cutting edge research and treatment of patients with various conditions including cancer, chronic pain and epilepsy, is pleased to announce that following the Company's Annual General Meeting held on 30 December 2022, all resolutions were duly passed.

-ENDS-

For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies

   Tel:                                                      +44 771 198 0221 
   Stene Jacobs                                       stene@apollon.org.uk

Peterhouse Capital Limited (Corporate Adviser)

   Tel:                                                       +44 207 220 9795 
   Guy Miller                                            gm@peterhousecapital.com

BlytheRay (Financial PR/IR-London)

   Tel:                                                       +44 207 138 3204 
   Tim Blythe/Megan Ray                     apollon@blytheray.com

About Apollon Formularies and Apollon Formularies Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

Apollon's proprietary medical cannabis formulations have undergone third-party testing which demonstrated the successful killing of nearly 100% of prostate, triple negative and HER2+ breast cancer cells in 3D cell cultures. Apollon's products are also used to treat patients suffering from different conditions, including chronic pain and epilepsy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFVFFELIVIF

(END) Dow Jones Newswires

December 30, 2022 07:37 ET (12:37 GMT)

Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Apollon Formularies Charts.
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Apollon Formularies Charts.